Assessing predictors of brachytherapy utilization among cervical cancer patients in Nigeria: evidence from a tertiary cancer centre Authors: Bolanle Adegboyega, Onyinye Balogun, Joy Ogunmuyiwa, Muhammad Habeebu, Okezie Ibeleme, Emmanuel Ojiebun, Oluwatomisin Abraham, Bukola Oshikanlu, Temitope Andero, Pearly Khaw, Anuja Jhingran Published: 2026 ABSTRACT AbstractBackgroundBrachytherapy is required for curative management of cervical cancer, but it is resource-intensive and technically challenging. There is limited data describing brachytherapy utilisation and its predictive factors influencing it in low- and middle-income countries, including Nigeria. This study assessed the trend of brachytherapy utilisation and its predictors among cervical cancer patients in Nigeria.MethodsWe conducted a retrospective study of patients treated for cervical cancer (stage I–IVA) at Medserve-LUTH Cancer Centre between March 2021 and June 2024. Sociodemographic, clinical, and disease-related variables were summarized using descriptive statistics. Univariable and multivariable logistic regression models were used to identify predictors of brachytherapy utilization.ResultsAmong the 343 patients, average age was 57.82 ± 11.77 years, 242 (70.55%) had stage II or III disease, and 173 (50.43%) received brachytherapy. Age, religion, disease stage, employment status, abdominopelvic pain at presentation, treatment delay, and menopausal state were significantly associated with brachytherapy utilization on univariable analysis (all p < 0.05). Women with increasing age, advanced disease, abdominopelvic pain at presentation, longer treatment delay, and who were Muslims had lower odds of brachytherapy utilization, while employed or premenopausal women had higher odds. On multivariable logistic regression, increasing age (p = 0.005, OR = 0.953, 95% CI = 0.921–0.986), religion (p = 0.003, OR = 0.346, 95% CI = 0.171–0.701), and treatment delay (p = 0.037, OR = 0.929, 95% CI = 0.868–0.996) remained independent predictors of lower brachytherapy utilization.ConclusionThis study shows disparities in brachytherapy utilization and suggests that religious beliefs and treatment delay limit access to curative treatment. These disparities may be addressed by intensifying education about early screening, early presentation, and adherence to treatment, especially in religious settings and among religious leaders. However, further studies need to be carried out on a larger population.Keywords: Brachytherapy Utilisation, Cervical Cancer, Predictors, Sub-Saharan Africa, Nigeria Background The incidence of cervical cancer is rising globally and currently stands as the fourth most common type of female cancer, with approximately 662,044 new cervical cancer cases and 348,709 deaths per year [1]. While the prevalence of cervical cancer has decreased in high-income countries (HICs) due to effective screening programs, reduced risk of high-risk persistent human papillomavirus (HPV) infection, which is attributed to organized screening programmes and provision of infrastructure for appropriate follow-up and treatment, the same cannot be said for low-and middle-income countries (LMICs), where the incidence and mortality are high. In LMICs, cervical cancer accounts for 20–30% of all female cancers, and nearly 9 out of 10 (87%) cervical cancer deaths occur in LMICs [2, 3]. In Africa, the prevalence and death rate of cervical cancers are on the rise, with almost 60,000 women dying of cervical cancer each year [4]. Cervical cancer is the leading cause of cancer death among women in sub-Saharan Africa [5]. Sub-Saharan Africa faces major challenges in the management of cervical cancer, which has resulted in a very high mortality rate. The five-year survival rates across sub-Saharan Africa vary from 24.0% in Kampala, Uganda, to a high of 82.1% in Mauritius, influenced by the Human Development Index [4, 6]. In Nigeria, the most populous country in Africa, cervical cancer is the second most common cancer [7, 8] affecting women, with about 10,000 new diagnoses and over 8000 deaths occurring yearly. Also, around 36.6 million female Nigerians over 15 years are at risk of developing cervical cancer [8]. The standard treatment for women with stage IIB to stage IVA cervical cancer comprises external beam radiation therapy (EBRT) and brachytherapy with concurrent chemotherapy [9–11]. Although surgery is the mainstay of treatment in early stages, chemoradiation is an option from stage IB2 onwards according to the NCCN guideline, and may be the preferred option in some cases [12]. Brachytherapy allows for a higher radiation dose to the cervix and surrounding areas while minimising radiation dose to critical adjacent structures, thereby reducing toxicity and significantly enhancing pelvic disease control and overall survival rates [13, 14]. However, compared with EBRT, it is a resource-intensive and technically challenging procedure. Particularly in low- and middle-income countries, technical difficulties include unreliable electricity, a shortage of local expertise for equipment maintenance, and an insufficient number of trained personnel to operate the machinery. Additionally, there are non-technical challenges, such as a lack of political commitment, inadequate funding, and competing healthcare priorities, including human immunodeficiency virus, malaria, tuberculosis, and other neglected tropical diseases [15]. Currently, most countries in sub-Saharan Africa lack brachytherapy facilities, causing delays in treatment, while some countries, like Nigeria, only have a few centres [16]. Sometimes, patients have to travel across borders to neighbouring countries to access brachytherapy services [15]. There is little information available on the utilisation of brachytherapy and factors associated with the utilisation of brachytherapy in the treatment of cervical cancer in sub-Saharan Africa and Nigeria. This study aims to describe the trend of brachytherapy utilisation and identify its predictors among cervical cancer patients in Nigeria. Materials and methods Study area Medserve-Lagos University Teaching Hospital Cancer Centre (Medserve-LUTH Cancer Centre MLCC) is an outpatient cancer centre established in 2019 as a Joint Venture between the NSIA Healthcare Development Investment Company (NHDIC) and the Lagos University Teaching Hospital (LUTH). It is located within the Lagos University Teaching Hospital, a federal tertiary teaching hospital that provides tertiary healthcare services in the Lagos area. Medserve-LUTH Cancer Centre has Nigeria’s largest, most experienced, and skilled oncology workforce. The centre is currently equipped with three multi-energy Linear Accelerators, a 16-slice CT-simulator and an intrinsic treatment planning system, a full-range high-dose-rate Iridium-192 brachytherapy after-loader system, mould and planning rooms and equipment, as well as a modern twenty-chair capacity chemotherapy suite and biosafety cabinet, making it the best-equipped radiation oncology centre in the sub-region of Africa outside of South Africa. The centre is staffed by 10 consultant oncologists who lead a team of medical and radiation physicists, radiation therapists, as well as oncology pharmacists, nurses, and support staff, and is surrounded by the wider hospital setting of specialists from all fields. Study design This was a retrospective study conducted at the Medserve-LUTH Cancer Centre. Patients with histologically diagnosed cancer of the cervix (stage I to IVA) who were treated between March 2021 and June 2024 at the centre were included in the study. Tumours were classified according to the 2018 International Federation of Gynecologists and Obstetricians (FIGO) staging system. Brachytherapy utilization was defined as the administration of at least 1 course of brachytherapy to a patient with cervical cancer during the course of the illness. Ethical approval This study obtained approval from the Lagos University Teaching Hospital Health Research Ethics Committee (LUTHHREC). HREC assigned number is ADM/DSCST/HREC/APP/6669. Data analysis Sociodemographic, clinical (including past medical and family history), disease-related, and treatment data of patients were retrieved from electronic medical records. History of comorbidities, such as hypertension, diabetes, and retroviral disease (RVD), was noted. Waiting time was defined as the number of days from histopathological diagnosis of cervical cancer to the first dose of chemotherapy or radiotherapy received, depending on treatment modality.Descriptive statistics were used to summarise patient characteristics. Univariable and multivariable logistic regression models were used to evaluate the relationship between brachytherapy utilization and other variables. Missing data points for any variable were excluded from regression analyses. A p value < 0.05 was considered statistically significant. Data was analysed using SPSS statistical software. Results The sociodemographic characteristics of patients are presented in Table 1. Among the 343 patients with cervical cancer in the study period, the mean age was 57.82 ± 11.77 years. The majority of patients were between 51 and 60 years old (101, 29.5%), followed by 61-70 years old (96, 27.99%). More than half of patients were self-employed (171, 51.6%), 69 were employed (21.2%), and 40 were retired (11.66%). Most (336) were non-smokers, and 25.07% consumed alcohol. Table 1Sociodemographic characteristicsCharacteristicsFrequencyPercentage (%)Age at Presentation (N = 395) ≤ 3030.87 31–40236.71 41–507020.41 51–6010129.45 61–709627.99 >=715014.58Marital Status Married24270.55 Widowed6017.49 Divorced102.92 Single92.62 Not Available226.41Employment status Employed6920.12 Self employed17751.60 Retired4011.66 Unemployed164.66 Not Available4111.95Social habits Alcohol History8625.07 Smoking History72.04 Sociodemographic characteristics Table 2 shows the clinical and disease characteristics of the patients. Majority were postmenopausal (266, 77.55%), and 23 (6.71%) had retroviral disease. More than one-third (131, 38.19%) had stage II disease, while 59 (17.21%) had stage IV. Squamous cell carcinoma was the most common histology, accounting for 85.71%. About half (49.27%) of the patients did not present with comorbidities, while 35.86% presented with only one comorbidity, and the rest had two or more. With respect to treatment modality, 91 patients (26.53%) had chemoradiation; overall, 178 (51.9%) had brachytherapy. Table 2Clinical characteristicsCharacteristicsFrequencyPercentage (%)Weight loss7521.87Fatigue5014.58Abdomino-pelvic pain10931.78Abnormal vagina discharge18052.48Mass in the Cervix6819.83Bleeding per vagina26978.43Multiple Sexual Partners4111.95Family History of Cervical Cancer20.58Family History of other cancers3510.20Stage I4212.24 II13138.19 III11132.36 IVA5917.21Histology Squamous cell carcinoma29485.71 Adenocarcinoma3510.20 Others144.08Comorbidities Yes17450.73 No16949.27Number of Comorbidities 014742.86 112335.86 26619.24 361.75 410.29 Hypertension14441.98 Diabetes3911.37 Peptic Ulcer Disease205.83 Retro-Viral Disease236.71 Others5215.16Waiting time for treatment 0–3 months21562.68 4–6 months7622.16 7–9 months308.75 10–12 months61.75 > 12 months164.66Treatment Modalities Brachytherapy72.04 External Beam Radiation Therapy (EBRT)8925.5 Brachytherapy + Chemotherapy00.00 Brachy + EBRT8023.32 Chemo + EBRT7622.16 Brachy + EBRT + Chemo9126.53 Clinical characteristics Univariable logistic regression Sociodemographic factors Age, religion, and employment status were significantly associated with brachytherapy utilization. For every 1-year increase in age, the odds of brachytherapy utilization decreased by about 4% (p < .001). Muslims had about 53% lower odds of brachytherapy utilization than Christians (Odds ratio [OR]= 0.475, 95% confidence interval [CI]= 0.266–0.851). Compared to employed women, retired and self-employed women had significantly lower odds of brachytherapy utilization. Unemployed women also had lower odds, but this was not statistically significant. Primary language of communication, residing in the same city as the radiotherapy centre (or not), and marital status did not show significant associations with brachytherapy utilization. Clinical characteristics The presence of abdominopelvic pain at presentation (p=0.032, OR = 0.609, 95% CI: 0.386–0.961) was associated with lower odds of receiving brachytherapy. Compared to postmenopausal women, premenopausal women had higher odds of brachytherapy utilization (p=0.02, OR = 1.844, 95% CI: 1.094–3.11). Other clinical characteristics like presence of vaginal bleeding, comorbidities, smoking, alcohol use, and previous oncological surgery were not associated with brachytherapy utilization. Disease-related factors Disease stage was strongly associated with brachytherapy utilization. Compared to stage I disease, women with stage IVA disease had 60% reduction in the odds of receiving brachytherapy (p=0.028, OR = 0.404, 95% CI: 0.18–0.907). Stage II and III did not show statistically significant associations. Treatment delay had significant association with brachytherapy utilization (p = 0.003). With every unit increase in the number of months before treatment, the odds of brachytherapy utilization reduced by about 7% (OR=0.931, 95% CI=0.877-0.989). Figure 1 presents the odds ratios and 95% confidence intervals for all variables with significant associations on univariable analysis. Odds ratios and 95% confidence intervals (shown as error bars) for variables that had a significant association with brachytherapy utilization on univariable logistic regression Multivariable logistic regression Two multivariable models were tested. The first model (M1) contained only the variables that had significant association with brachytherapy utilization on univariable regression. In this model, age (p= 0.003, OR= 0.951, 95% CI= 0.919–0.983) and religion (p= 0.007, OR= 0.388, 95% CI= 0.196–0.769) persisted as independent predictors of brachytherapy utilization. Employment status, stage, and menopausal status were no longer significant predictors of brachytherapy utilization. The second multivariable model included menopausal state, awareness of Pap smear, chemotherapy administration, and presence of cervical mass on vaginal examination at presentation (all p ≤ 0.2 during univariable logistic regression), in addition to the variables in model 1. No association was found between brachytherapy utilization and these additional variables, whereas age (p= 0.005, OR= 0.953, 95% CI= 0.921–0.986), religion (p= 0.003, OR= 0.346, 95% CI= 0.171–0.701), and waiting time (p= 0.037, OR= 0.929, 95% CI= 0.868–0.996) remained significant predictors of brachytherapy utilization. Discussion Brachytherapy combined with EBRT and chemotherapy constitutes the standard of care for locally advanced cervical cancer. With brachytherapy, curative radiation doses can be safely delivered to the tumour while sparing organs at risk, thereby improving local control and survival [17]. This study assessed brachytherapy utilization and its predictors in a tertiary centre in Nigeria. Over the study period, the brachytherapy utilization rate was 51.9%, and age, religion, and waiting time were independent predictors of brachytherapy utilisation. Previous studies have suggested, similarly, that age, especially old age, influences treatment patterns and utilization [18]. Eakin et al. showed that older people are less likely to receive brachytherapy, and other studies have shown that brachytherapy utilisation usually decreases with age [19]. This could be due to the inability of older people to tolerate the procedure (given its invasive nature) and poorer prognosis with increasing age, even after standard treatment has been administered. Religion was found to be an independent predictor of brachytherapy utilisation in this study, as the Muslim women had lower odds of receiving brachytherapy. Although literature on the relationship between religion and brachytherapy utilisation is sparse, a study by Rachelle 2014 showed that Muslims view illnesses as a test of faith, and this may affect their treatment adherence. Although they are encouraged to seek treatment for curable diseases, their belief may lead them to prioritise spirituality over physical healing [20]. This is also supported by other study on cervical screening uptake, which stated culture and religion stand as a social barrier to cervical screening among Muslim women [21, 22]. The duration between presentation and commencement of treatment (waiting time) was another independent predictor of brachytherapy utilization. It was observed that increased waiting time reduced the odds of brachytherapy utilization. Long waiting times are a reflection of the particular challenges of brachytherapy in LMICS, namely poor financial capacity of patients, limited infrastructure, and inadequate manpower. The treatment delay that results can lead to tumor progression and worsening debility, which may eventually prevent some patients from benefiting from brachytherapy. The long-reaching consequences are poor treatment response, poor prognosis, and increased mortality [23]. Some other variables were significantly associated with brachytherapy utilization on univariable analysis. Although they did not emerge as independent predictors due to the confounding effects of other variables, they merit discussion. The significant association between employment status and utilisation of brachytherapy on univariable analysis in this study shows that socioeconomic factors, such as employment status, can influence access to advanced treatment techniques. This finding aligns with previous studies that have shown that financial constraint and employment status significantly affect health-seeking behaviour and access to advanced cancer therapies in LMICs [24–26]. It also aligns with findings from High-Income Countries (HIC), where studies showed that lower income and lack of insurance are associated with reduced access to brachytherapy [19, 27, 28]. In many countries in sub-Saharan Africa, there is limited health insurance coverage, and patients have to bear the burden of healthcare costs, including those related to transportation and accommodation during treatment. Although employment may not be a direct measure of income, those employed may have better financial capacity and health insurance that facilitates access to advanced oncology services, while retired patients have to rely on small and irregular pension or support from relatives and friends. Moreover, patients who are employed may have better access to health education through prior experience with formal healthcare systems. A significant association between advanced disease stage and brachytherapy utilisation was observed, with stage IVA showing the lowest odds of brachytherapy utilisation. However, a substantial proportion of patients still present with advanced disease in LMICs due to absent screening infrastructure, poor referral systems, and geographic inaccessibility to health facilities [25, 26]. This aligns with the finding by Eakin et al. that stage IV patients are less likely to receive brachytherapy [19]. The standard treatment for women with stage IIB to stage IVA cervical cancer comprises external beam radiation therapy (EBRT) and brachytherapy with concurrent chemotherapy. Brachytherapy offers significant improvement in local control and overall survival [29, 30]. However, advanced disease may be associated with poor performance status, necessitating decisions to prioritise symptom relief over curative treatment. In settings such as ours, patients who present with advanced disease have also likely spent a lot of money on alternative therapies, leaving them unable to afford standard care when they eventually present in the hospital. This finding highlights the fact that early detection and timely referral for expert care are highly important for increasing the chances of utilization of standard curative treatmentSummarily, the low utilisation of brachytherapy noted in this study can be attributed to socioeconomic and disease factors, which are often interrelated. In developing countries, cultural norms, religious beliefs, and high out-of-pocket healthcare costs contribute to advanced disease presentation, treatment delays, and access to standard treatment modalities. Limitations Our study is limited by its retrospective design and is prone to recall bias and incomplete data; data on healthcare financing, for instance, was not available for analysis. This is also a single-centred study, and this could reduce its generalizability. Additionally, selection bias may be present due to the single-center design and referral patterns to a tertiary cancer center, which may not represent the broader cervical cancer population in Nigeria. Furthermore, the sample size may mask subtle associations between variables and brachytherapy utilization. Notwithstanding these limitations, the study represents findings from a high-volume oncology centre in the most populous African nation and offers insight into brachytherapy utilization trends and predictors in the region. Conclusion This study has assessed brachytherapy utilisation and its predictors in a foremost oncology centre in an LMIC. Although brachytherapy is essential for curative management of cervical cancer, only half of the patients in our study utilized it. Age, religious beliefs, and treatment waiting times were significant predictors of brachytherapy utilization, highlighting the need for concerted efforts towards early detection, community engagement, and health system strengthening to minimize treatment delay. Acknowledgements All authors are acknowledged for their contributions to the completion of this review. Abbreviations Low-and middle-income countries High-income countries Human Papillomavirus External Beam Radiation Therapy International Atomic Energy Agency Intensity Modulated Radiation Therapy Authors’ contributions B A, O A conceptualised the study, analysed and interpreted the survey data. All authors were contributors to writing the manuscript. All authors read and approved the final manuscript. Funding Not applicable. Data availability The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate This is a retrospective study. This research was conducted in strict adherence to the ethical principles outlined by the Declaration of Helsinki. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.